CONy 2021 | Current and emerging therapeutics for NMOSD

Nikolaos Grigoriadis, MD, PhD, Aristotle University of Thessaloniki, Thessaloniki, Greece, talks on existing and emerging treatment for neuromyelitis optica spectrum disorders (NMOSD). Many of the commonly used preventive therapies for NMOSD are cell-depleting immunosuppressants. Treatments targeting the selective depletion of B-cells might also be beneficial and contribute to a better control of relapses. Additionally, inhibition of the complement system might also contribute to a better outcome. There are several clinical trials currently running, and it is expected that recommendations on particular factors interfering with complement activation will soon be available. This interview was conducted during the virtual 2021 World Congress on Controversies in Neurology (CONy).